全球DNA连接酶市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析、未来预测（2026-2034）

DNA连接酶市场成长驱动因素

2025年全球DNA连接酶市场规模为3.7822亿美元，预计将从2026年的4.112亿美元成长到2034年的8.3046亿美元，预测期内年复合成长率（CAGR）为9.18%。北美地区凭藉着强大的生物技术基础、不断成长的基因治疗研究以及基因编辑工具的快速普及，在2025年占据了51.21%的市场占有率，成为市场主导者。

市场概览

DNA连接酶是催化DNA片段之间磷酸二酯键形成的关键酶，实现DNA修復、复製和重组。在分子生物学和生物技术产业，这些酵素广泛应用于DNA克隆、次世代定序（NGS）文库建构、基因合成和基因组编辑。

基因工程、合成生物学和基因组研究的进步，以及对细胞和基因治疗日益成长的需求，推动市场稳步扩张。Thermo Fisher Scientific、Takara Bio Inc. 和 New England Biolabs 等领先公司凭藉其丰富的产品组合和全球分销网路，占据了显着的市场占有率。

市场动态

市场驱动因素

基因编辑技术的进步

基因编辑技术的快速发展，特别是 CRISPR-Cas9 技术，是推动市场成长的主要动力。 DNA 连接酶在基因工程过程中修復 DNA 链方面发挥着非常重要的作用。随着基于 CRISPR 的疗法在癌症治疗、遗传性疾病和自体免疫疾病领域中得到更广泛的应用，对高效连接酶的需求持续成长。

2024年 9月，KSQ Therapeutics 获得美国 FDA 批准，启动其采用 CRISPR 技术的TIL 疗法候选药物的I/II 期临床试验。这显示依赖DNA连接酶的临床应用日益增多。

市场限制因子

技术挑战与熟练人员短缺

儘管基因编辑具有很高的成长潜力，但脱靶效应引发了安全性和监管的担忧。2024年初发表的论文指出，由于非预期的基因组修饰，CRISPR技术有其限制。此外，递送系统设计、酵素生产规模化以及熟练专业人员短缺等方面的挑战可能会限制市场扩张。

市场机会

策略联盟与业务拓展

各公司正积极寻求併购和联盟，以扩展其基因组技术组合。例如，2021年9月，Fortis Lifesciences收购了Empire Biosciences，增强了其重组蛋白和酵素的生产能力。进军亚太市场将带来更多成长机会。

市场挑战

先进连接酶的高成本限制了其在小型研究机构和发展中国家的应用。此外，基因工程工具严格的监管架构可能会延缓产品审批和商业化进程。

市场趋势

日益关注细胞和基因治疗

随着个人化医疗和基于细胞的基因疗法的不断发展，新的市场趋势涌现。2025年3月，Neurotec Pharmaceuticals获得FDA核准用于细胞基因治疗，显示克隆和基因编辑工具（包括DNA连接酶）的重要性日益凸显。

对酵素技术创新和高效连接酶变体的策略性投资进一步增强了市场前景。

市场区隔分析

依类型

市场依类型分为T4 DNA连接酶、T7 DNA连接酶和其他连接酶。

• 由于T4 DNA连接酶在克隆和基因工程应用中的高效性和多功能性，在2025年占据市场主导地位。
• 受合成生物学和生物製药研究领域应用日益广泛推动，预计直至2034年T7 DNA连接酶的年复合成长率将最高。
• 其他类别（包括耐热连接酶）在PCR和分子诊断应用领域日益受到关注。

依应用领域划分

基因组学和基因工程领域在2025年占据最大占有率，这得益于基于CRISPR的基因编辑技术和合成生物学的快速发展。

药物发现和研究领域预计到2034年将以更高的年复合成长率成长，这主要得益于对个人化医疗和合作研究计画投资的增加。

此外，随着PCR和NGS技术的日益普及，诊断应用也不断扩展。

依最终使用者划分

2025年，製药和生物技术公司占据最大市场占有率，这主要得益于大规模基因治疗和疫苗开发计画的推进。

学术和研究机构构成了一个强大的第二大细分市场，这主要得益于基因组研究经费的增加。

其他细分领域，包括合约研究组织（CRO）和诊断实验室，由于遗传疾病的日益普遍以及对分子诊断需求的成长而扩张。

区域展望

北美

到2025年，北美市场规模达到 1.9368亿美元，凭藉先进的研究基础设施和战略收购，保持其领先地位。美国仍然是主要贡献者，这得益于基因编辑工具的快速普及。

欧洲

到2025年，欧洲占据第二大市场占有率，这得益于其在基因组学领域的强大学术研究和政府投资。德国和英国引领着该地区的研发活动。

亚太地区

预计到2034年，亚太地区将以最高的年复合成长率成长，这主要得益于生物技术製造业的扩张以及诸如Cytiva在中国开展的合作等伙伴关係。

拉丁美洲、中东和非洲

这些地区正经历温和成长，这主要得益于基因组学计画的扩展和对精准医疗投资的增加。沙乌地阿拉伯基因组计画显着加速了GCC地区的定序工作。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

• 市场驱动因素
• 市场限制因素
• 市场机会
• 市场趋势

第4章 主要考察

• DNA修饰技术进展
• 基因工程技术进展
• 主要公司新产品发布
• 关键产业趋势：併购、商业合作等
• 新冠疫情的影响市场

第5章 全球DNA连接酶市场分析：洞察与预测（2021-2034）

• 市场分析、洞察与预测：依类型划分
  • T7 DNA
  • T4 DNA
  • 其他
• 市场分析、洞察与预测：依应用划分
  • 基因体学与基因工程
  • 药物发现与研究
  • 其他
• 市场分析、洞察与预测：依最终用户划分
  • 製药和生技公司
  • 学术和研究机构
  • 其他
• 市场分析、洞察与预测：依地区划分
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第6章 北美DNA连接酶市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 美国
  • 加拿大

第7章 欧洲DNA连接酶市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 义大利
  • 斯堪的纳维亚
  • 其他欧洲地区

第8章 亚太地区DNA连接酶市场分析：洞察与预测（2021-2034）

• 依国家/地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 东南亚
  • 其他亚太地区

第9章 拉丁美洲DNA连接酶市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 巴西
  • 墨西哥
  • 其他拉丁美洲国家

第10章 中东与非洲DNA连接酶市场分析：洞察与预测（2021-2034）

• 依国家划分
  • GCC国家
  • 南非
  • 其他中东和非洲国家

第11章 竞争分析

• 全球市场占有率分析（2025年）
• 公司简介
  • Thermo Fisher Scientific Inc.
  • New England Biolabs
  • Danaher Corporation
  • Fortis Life Sciences, LLC.
  • Promega Corporation
  • Bio-Rad Laboratories, Inc.
  • BioCat GmbH
  • Takara Bio Inc.
  • Agilent Technologies, Inc.

Growth Factors of DNA ligases Market

The global DNA ligases market was valued at USD 378.22 million in 2025 and is projected to grow from USD 411.2 million in 2026 to USD 830.46 million by 2034, registering a CAGR of 9.18% during the forecast period. North America dominated the market with a 51.21% share in 2025, driven by strong biotechnology infrastructure, increasing gene therapy research, and rapid adoption of gene editing tools.

Market Overview

DNA ligases are essential enzymes that catalyze the formation of phosphodiester bonds between DNA fragments, enabling DNA repair, replication, and recombination. In molecular biology and biotechnology industries, these enzymes are widely used for DNA cloning, next-generation sequencing (NGS) library preparation, gene synthesis, and genome editing.

The market is witnessing steady expansion due to advancements in genetic engineering, synthetic biology, genomics research, and increasing demand for cell and gene therapies. Leading players such as Thermo Fisher Scientific Inc., Takara Bio Inc., and New England Biolabs hold significant shares due to their extensive product portfolios and global distribution networks.

Market Dynamics

Market Drivers

Advancements in Gene Editing Technologies

The rapid evolution of gene editing technologies, particularly CRISPR-Cas9, is a major growth driver. DNA ligases play a crucial role in repairing DNA strands during gene manipulation processes. As CRISPR-based therapies gain traction in oncology, genetic disorders, and autoimmune diseases, demand for high-efficiency ligases continues to rise.

In September 2024, KSQ Therapeutics received U.S. FDA clearance to initiate a Phase 1/2 clinical trial for its CRISPR-engineered TIL therapy candidate, highlighting increasing clinical applications that rely on DNA ligases.

Market Restraints

Technical Complications and Skilled Workforce Shortage

Despite strong growth potential, off-target effects in gene editing raise safety and regulatory concerns. Articles published in early 2024 highlight limitations of CRISPR due to unintended genomic modifications. Additionally, challenges in designing delivery systems, scaling enzyme production, and the shortage of skilled professionals may restrain market expansion.

Market Opportunities

Strategic Collaborations and Expansions

Companies are actively pursuing mergers, acquisitions, and partnerships to expand their genomic technology portfolios. For example, in September 2021, Fortis Life Sciences acquired Empirical Bioscience to strengthen its recombinant protein and enzyme manufacturing capabilities. Expansion into Asia Pacific markets presents additional growth opportunities.

Market Challenges

High costs of advanced ligase enzymes limit accessibility for small research institutions and developing countries. Moreover, strict regulatory frameworks surrounding genetic engineering tools can slow product approvals and commercialization.

Market Trends

Rising Focus on Cell & Gene Therapies

The growing shift toward personalized medicine and cell-based gene therapies is shaping new market trends. In March 2025, Neurotech Pharmaceuticals received FDA approval for a cell-based gene therapy, underscoring the increasing importance of cloning and gene editing tools, including DNA ligases.

Strategic investments in enzyme innovation and high-efficiency ligase variants are further strengthening the market outlook.

Segmentation Analysis

By Type

The market is segmented into T4 DNA, T7 DNA, and others.

• T4 DNA ligase dominated the market in 2025 due to its high efficiency and versatility in cloning and genetic engineering applications.
• T7 DNA ligase is expected to grow at the highest CAGR through 2034, driven by increasing adoption in synthetic biology and biopharmaceutical research.
• The others segment, including thermostable ligases, is gaining traction in PCR and molecular diagnostics applications.

By Application

The genomics & genetic engineering segment held the largest share in 2025, supported by rapid advancements in CRISPR-based editing and synthetic biology.

The drug discovery & research segment is anticipated to grow at a higher CAGR through 2034, driven by rising investments in personalized medicine and collaborative research initiatives.

Diagnostics applications are also expanding due to growing adoption of PCR and NGS technologies.

By End-User

Pharmaceutical and biotechnology companies accounted for the largest market share in 2025, driven by extensive gene therapy and vaccine development programs.

Academic & research institutes represent a strong secondary segment, supported by increasing funding in genomics research.

The others segment, including CROs and diagnostic laboratories, is expanding due to rising genetic disease prevalence and demand for molecular diagnostics.

Regional Outlook

North America

North America generated USD 193.68 million in 2025, maintaining leadership due to advanced research infrastructure and strategic acquisitions. The U.S. remains the key contributor, supported by rapid adoption of gene editing tools.

Europe

Europe held the second-largest share in 2025, supported by strong academic research and government investments in genomics. Germany and the U.K. lead regional R&D initiatives.

Asia Pacific

Asia Pacific is projected to grow at the highest CAGR through 2034, driven by expanding biotechnology manufacturing and partnerships such as Cytiva's collaboration in China.

Latin America & Middle East & Africa

These regions are witnessing gradual growth due to expanding genomics programs and rising investment in precision medicine. The Saudi Genome Program has significantly accelerated sequencing initiatives in the GCC region.

Competitive Landscape

The market is semi-consolidated with key players including:

• Thermo Fisher Scientific Inc.
• New England Biolabs
• Takara Bio Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Promega Corporation
• Danaher Corporation
• Fortis Life Sciences, LLC.

Strategic investments, manufacturing expansions, and R&D collaborations continue to strengthen competitive positioning.

Conclusion

The global DNA ligases market is poised for substantial growth, expanding from USD 378.22 million in 2025 to USD 830.46 million by 2034, at a CAGR of 9.18%. Rising advancements in gene editing, increasing clinical trials in cell and gene therapies, and expanding genomics research are key growth drivers. While high enzyme costs and regulatory challenges may restrain adoption, strategic collaborations and innovation in high-efficiency ligases are expected to sustain long-term market expansion across global biotechnology and pharmaceutical sectors.

Segmentation By Type

• T7 DNA
• T4 DNA
• Others

By Application

• Genomics & Genetic Engineering
• Drug Discovery & Research
• Others

By End-user

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• Others

By Region

• North America (By Type, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, End-user, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Application, End-user, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Application, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Application, End-user, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in DNA Modification Techniques
• 4.2. Technological Advancements in Genetic Engineering
• 4.3. New Product Launches, By Key Players
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnership, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. T7 DNA
  • 5.1.2. T4 DNA
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Genomics & Genetic Engineering
  • 5.2.2. Drug Discovery & Research
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Pharmaceutical and Biotechnology Companies
  • 5.3.2. Academic & Research Institutes
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. T7 DNA
  • 6.1.2. T4 DNA
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Genomics & Genetic Engineering
  • 6.2.2. Drug Discovery & Research
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Pharmaceutical and Biotechnology Companies
  • 6.3.2. Academic & Research Institutes
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. T7 DNA
  • 7.1.2. T4 DNA
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Genomics & Genetic Engineering
  • 7.2.2. Drug Discovery & Research
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Pharmaceutical and Biotechnology Companies
  • 7.3.2. Academic & Research Institutes
  • 7.3.3. Others
• 7.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. T7 DNA
  • 8.1.2. T4 DNA
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Genomics & Genetic Engineering
  • 8.2.2. Drug Discovery & Research
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Pharmaceutical and Biotechnology Companies
  • 8.3.2. Academic & Research Institutes
  • 8.3.3. Others
• 8.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. T7 DNA
  • 9.1.2. T4 DNA
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Genomics & Genetic Engineering
  • 9.2.2. Drug Discovery & Research
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Pharmaceutical and Biotechnology Companies
  • 9.3.2. Academic & Research Institutes
  • 9.3.3. Others
• 9.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East and Africa DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. T7 DNA
  • 10.1.2. T4 DNA
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Genomics & Genetic Engineering
  • 10.2.2. Drug Discovery & Research
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Pharmaceutical and Biotechnology Companies
  • 10.3.2. Academic & Research Institutes
  • 10.3.3. Others
• 10.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
  • 11.2.1. Thermo Fisher Scientific Inc.
  • 11.2.2. New England Biolabs
  • 11.2.3. Danaher Corporation
  • 11.2.4. Fortis Life Sciences, LLC.
  • 11.2.5. Promega Corporation
  • 11.2.6. Bio-Rad Laboratories, Inc.
  • 11.2.7. BioCat GmbH
  • 11.2.8. Takara Bio Inc.
  • 11.2.9. Agilent Technologies, Inc.

List of Tables

• Table 1: Global DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Table 2: Global DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Table 3: Global DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Table 4: Global DNA Ligases Market Revenue (USD million) Forecast, by Region, 2021-2034
• Table 5: North America DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Table 6: North America DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Table 7: North America DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Table 8: North America DNA Ligases Market Revenue (USD million) Forecast, By Country, 2021-2034
• Table 9: Europe DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Table 10: Europe DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Table 11: Europe DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Table 12: Europe DNA Ligases Market Revenue (USD million) Forecast, by Country/Sub-Region, 2021-2034
• Table 13: Asia Pacific DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Table 14: Asia Pacific DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Table 15: Asia Pacific DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Table 16: Asia Pacific DNA Ligases Market Revenue (USD million) Forecast, By Country/Sub-Region, 2021-2034
• Table 17: Latin America DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Table 18: Latin America DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Table 19: Latin America DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Table 20: Latin America DNA Ligases Market Revenue (USD million) Forecast, By Country/Sub-Region, 2021-2034
• Table 21: Middle East & Africa DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Table 22: Middle East & Africa DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Table 23: Middle East & Africa DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Table 24: Middle East & Africa DNA Ligases Market Revenue (USD million) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

• Figure 1: Global DNA Ligases Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
• Figure 2: Global DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Figure 3: Global DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Figure 4: Global DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Figure 5: Global DNA Ligases Market Value (USD million), by Region, 2025 & 2034
• Figure 6: North America DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Figure 7: North America DNA Ligases Market Value Share (%), by Type, 2025
• Figure 8: North America DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Figure 9: North America DNA Ligases Market Value Share (%), by Application, 2025
• Figure 10: North America DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Figure 11: North America DNA Ligases Market Value Share (%), by End-user, 2025
• Figure 12: North America DNA Ligases Market Value (USD million), By Country, 2025 & 2034
• Figure 13: North America DNA Ligases Market Value Share (%), By Country, 2025
• Figure 14: Europe DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Figure 15: Europe DNA Ligases Market Value Share (%), by Type, 2025
• Figure 16: Europe DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Figure 17: Europe DNA Ligases Market Value Share (%), by Application, 2025
• Figure 18: Europe DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Figure 19: Europe DNA Ligases Market Value Share (%), by End-user, 2025
• Figure 20: Europe DNA Ligases Market Value (USD million), By Country/Sub-Region, 2025 & 2034
• Figure 21: Europe DNA Ligases Market Value Share (%), By Country/Sub-Region, 2025
• Figure 22: Asia Pacific DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Figure 23: Asia Pacific DNA Ligases Market Value Share (%), by Type, 2025
• Figure 24: Asia Pacific DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Figure 25: Asia Pacific DNA Ligases Market Value Share (%), by Application, 2025
• Figure 26: Asia Pacific DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Figure 27: Asia Pacific DNA Ligases Market Value Share (%), by End-user, 2025
• Figure 28: Asia Pacific DNA Ligases Market Value (USD million), By Country/Sub-Region, 2025 & 2034
• Figure 29: Asia Pacific DNA Ligases Market Value Share (%), By Country/Sub-Region, 2025
• Figure 30: Latin America DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Figure 31: Latin America DNA Ligases Market Value Share (%), by Type, 2025
• Figure 32: Latin America DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Figure 33: Latin America DNA Ligases Market Value Share (%), by Application, 2025
• Figure 34: Latin America DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Figure 35: Latin America DNA Ligases Market Value Share (%), by End-user, 2025
• Figure 36: Latin America DNA Ligases Market Value (USD million), By Country/Sub-Region, 2025 & 2034
• Figure 37: Latin America DNA Ligases Market Value Share (%), By Country/Sub-Region, 2025
• Figure 38: Middle East & Africa DNA Ligases Market Value Share (%), by Type, 2025 & 2034
• Figure 39: Middle East & Africa DNA Ligases Market Value Share (%), by Type, 2025
• Figure 40: Middle East & Africa DNA Ligases Market Value Share (%), by Application, 2025 & 2034
• Figure 41: Middle East & Africa DNA Ligases Market Value Share (%), by Application, 2025
• Figure 42: Middle East & Africa DNA Ligases Market Value Share (%), by End-user, 2025 & 2034
• Figure 43: Middle East & Africa DNA Ligases Market Value Share (%), by End-user, 2025
• Figure 44: Middle East & Africa DNA Ligases Market Value (USD million), By Country/Sub-Region, 2025 & 2034
• Figure 45: Middle East & Africa DNA Ligases Market Value Share (%), By Country/Sub-Region, 2025